[company_age]unknown[/company_age][employees]11-50 employees[/employees][funding]Series unknown[/funding][description]EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company specializing in the development and commercialization of medications for musculoskeletal and rare diseases. Their flagship product, Binosto®, for osteoporosis treatment, is successfully marketed by licensees across the US, Europe, Asia, and the Middle East. EffRx's business model prioritizes delivering superior clinical and commercial value propositions for physicians, payers, and patients. They actively seek in-licensing opportunities for niche therapeutic areas in Europe, with a particular focus on rare diseases, where they have received an orphan drug designation (ODD) from the FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA).[/description][ps]Prescription medications for rare endocrine and metabolic disorders as well as musculoskeletal diseases.[/ps]